Infections and Bacterial Resistance · Journal article

Quorum sensing gene abaI enhancing capsule production and pathogenicity of Acinetobacter baumannii

Frontiers in Microbiology · September 1, 2026

Hypothesis-Generating Why this matters to you Expert discussion

Raises a question worth testing. It does not answer one.

AI Summary

This is a mechanistic study demonstrating that the abaI quorum-sensing gene in a carbapenem-resistant A. baumannii strain enhances capsule production and virulence in a mouse lung infection model, acting via IL-17 and NF-κB inflammatory pathways. The work is hypothesis-generating regarding therapeutic targeting but provides no clinical trial data or efficacy evidence in humans.

What was studied

Experimental knockout study with murine infection model. Clinical carbapenem-resistant A. baumannii isolate with mucoid colonies (CRAB110); BALB/c mice (specific numbers not stated). Intervention: abaI gene knockout in CRAB110 using CRISPR/Cas9 system. Compared with: Wild-type CRAB110 strain.

Key findings

CRAB110Δ abaI knockout significantly reduced capsule production, virulence, and host inflammation compared to wild-type CRAB110 Mice infected with CRAB110Δ abaI exhibited reduced inflammation versus CRAB110 infection Transcriptomic analysis identified differentially expressed genes in polysaccharide synthesis (wza, wzb, wzc), galactose metabolism (GalM), ABC transport, and amino acid metabolism

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

This work suggests that blocking abaI-mediated quorum sensing may reduce A. baumannii virulence and inflammation, but the finding is preclinical and does not yet inform clinical practice. Therapeutic translation would require validation in additional strains and progression to in vivo efficacy and safety studies.

Plain-language summary

Mechanistic study in knockout bacteria and mouse models identifying a QS gene's role in virulence; lacks clinical outcome data and remains exploratory regarding therapeutic translation.

Study design

As stated by the source record.

MethodsA clinical carbapenem-resistant A. baumannii strain (CRAB110) was used to construct an abaI knockout strain using CRISPR/Cas9. Capsule production, bacterial virulence, and host immune responses were evaluated by assessing bacterial phenotypes, physiology, gene expression, and transcriptomic analysis. Mice were infected with CRAB110 or CRAB110Δ abaI, and lung transcriptomic and cellular responses were measured.

DesignExperimental knockout study with murine infection model

PopulationClinical carbapenem-resistant A. baumannii isolate with mucoid colonies (CRAB110); BALB/c mice (specific numbers not stated)

InterventionabaI gene knockout in CRAB110 using CRISPR/Cas9 system

ComparatorWild-type CRAB110 strain

Clinical bottom line

Caveats

Study uses single A. baumannii clinical isolate; generalizability to other CRAB or A. baumannii strains unknown
Mouse lung model employed; relevance to systemic human infection, bacteremia, or other clinical manifestations not established
Number of mice per group, statistical methods, and p-values not reported in text
No quantitative measurements of capsule thickness, bacterial burden, or inflammatory cytokine levels provided

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

moderate

Controlled CRISPR knockout with transcriptomic and in vivo validation; unblinded mouse infection model.

Directness

limited

Mouse lung infection model; mechanistic pathways identified but no human clinical outcome data.

Consistency

limited

Single bacterial strain; transcriptomic findings support phenotypic results but no external replication reported.

Risk of bias

moderate

No blinding mentioned in mouse studies; single CRAB strain limits generalizability across A. baumannii isolates.

Sample adequacy

insufficient

Number of mice and replicates per group not stated in text provided.

What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.

Source abstract

Introduction Acinetobacter baumannii ( A. baumannii ) is a Gram-negative coccobacillus that can cause a variety of infectious diseases. The Quorum Sensing (QS) system is a widespread mechanism regulating group behavior in bacteria, playing a crucial role in the virulence regulation of several Gram-negative pathogenic bacteria. The aim of this study was to investigate the effects of the A. baumannii quorum sensing system on capsule production and pathogenicity. Methods In this work, a clinical carbapenem-resistant A. baumannii with mucoid colonies (CRAB110) was used to construct an abaI knockout strain (CRAB110Δ abaI ) using CRISPR/Cas9 system. Afterwards, changes in capsule production, bacterial virulence, and host immune responses were evaluated by assessing bacterial phenotypes, physiology, gene expression, and effects on the host. Results The results showed that CRAB110Δ abaI significantly affected capsule production, virulence, and immunity compared with CRAB110. Mice infected with CRAB110Δ abaI exhibited a reduction in inflammation compared to those infected with CRAB110. A comparison of the transcriptomes of CRAB110 and CRAB110Δ abaI identified differentially expressed genes related to polysaccharide synthesis ( wza, wzb, wzc ), galactose metabolism ( GalM ), ABC transport, and amino acid metabolism. Mouse lung transcriptomic and cellular Western blot data indicated that quorum sensing (QS) exerts its pro-inflammatory effect through Acinetobacter baumannii by influencing the IL-17 and NF-κB pathways. Conclusion This study suggests that the abaI gene boosts capsule production and pathogenicity of A. baumannii, providing new insights for clinical management of drug-resistant A. baumannii diseases and a foundation for new antimicrobial drugs.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Infections and Bacterial ResistanceYu ZhengGuanfeng WuJian PengZhilang QiuPeiling ZhaoKexin Yuan